Standard BioTools (NASDAQ:LAB - Get Free Report) is expected to announce its Q1 2025 earnings results after the market closes on Tuesday, May 6th. Analysts expect the company to announce earnings of ($0.04) per share and revenue of $40.10 million for the quarter.
Standard BioTools Trading Down 1.3 %
Shares of NASDAQ LAB traded down $0.02 during trading on Tuesday, reaching $1.17. 178,238 shares of the company traded hands, compared to its average volume of 1,738,263. Standard BioTools has a 12-month low of $0.97 and a 12-month high of $2.74. The firm's fifty day simple moving average is $1.16 and its 200 day simple moving average is $1.56. The stock has a market cap of $441.52 million, a P/E ratio of -1.64 and a beta of 1.54.
Insider Activity at Standard BioTools
In related news, Director Casdin Partners Master Fund, L bought 4,820,959 shares of the firm's stock in a transaction that occurred on Friday, February 28th. The stock was purchased at an average cost of $1.06 per share, for a total transaction of $5,110,216.54. Following the completion of the acquisition, the director now owns 58,846,780 shares in the company, valued at approximately $62,377,586.80. This trade represents a 8.92 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 53.10% of the stock is currently owned by insiders.
Analyst Upgrades and Downgrades
Separately, KeyCorp downgraded shares of Standard BioTools from an "overweight" rating to a "sector weight" rating in a report on Thursday, February 27th.
View Our Latest Stock Analysis on LAB
Standard BioTools Company Profile
(
Get Free Report)
Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Standard BioTools, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Standard BioTools wasn't on the list.
While Standard BioTools currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
